

Cover Story
By Matthew Bin Han Ong
Utilization data compiled by Flatiron Health and made available to The Cancer Letter make it possible to visualize the dramatic uptake of immunotherapy drugs in the academic and community settings.
In Brief
Drugs & Targets
Trending Stories
- ACOG says it will no longer accept federal funding
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”
- Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills